var data={"title":"Iohexol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Iohexol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6389?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=iohexol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Iohexol: Patient drug information&quot;</a> and <a href=\"topic.htm?path=iohexol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Iohexol: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26524993\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Iohexol 140, 300 (imaging bulk), and 350 are not for intrathecal use.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183891\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Omnipaque</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9617644\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Omnipaque</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183894\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Contrast Agent;</li>\n      <li>\n        Iodinated Contrast Media;</li>\n      <li>\n        Radiological/Contrast Media (Nonionic, High Osmolality);</li>\n      <li>\n        Radiological/Contrast Media (Nonionic, Low Osmolality)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983659\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Concentration, volume, and rate may depend on the equipment, condition of injected vessel, size/condition of patient, and imaging technique used. Refer to prescribing information for detailed dosing and administration information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Intrathecal imaging: </b>\n      <b>Note:</b> gI = grams of iodine; mgI = mg of iodine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Myelography: Intrathecal: Iohexol 180, 240, or 300 only:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lumbar (lumbar injection):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 180: 10 to 17 mL (1.8 to 3.06 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 240: 7 to 12.5 mL (1.7 to 3 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Thoracic (lumbar or cervical injection) or cervical (lumbar injection):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 240: 6 to 12.5 mL (1.4 to 3 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 300: 6 to 10 mL (1.8 to 3 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cervical (c1-2 injection):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 180: 7 to 10 mL (1.3 to 1.8 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 240: 6 to 12.5 mL (1.4 to 3 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 300: 4 to 10 mL (1.2 to 3 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Total columnar (lumbar injection):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 240: 6 to 12.5 mL (1.4 to 3 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 300: 6 to 10 mL (1.8 to 3 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Single myelographic procedure: Do not exceed a concentration of 300 mgI/mL or total dose of iodine 3,060 mg. If a repeat procedure is required, wait at least 48 hours (5 to 7 days is preferred).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Intravascular imaging: Note:</b> gI = grams of iodine; mgI = mg of iodine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ventriculography: Iohexol 350: 40 mL (range 30 to 60 mL); may repeat as necessary. If combined with selective coronary arteriography, do not exceed a total volume of 250 mL (87.5 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective coronary arteriography: Iohexol 350: 5 mL (range 3 to 14 mL) per injection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aortic root and arch studies: Iohexol 350 (used alone): 50 mL (range: 20 to 75 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Combined angiocardiographic procedures: Maximum total dose for all procedures: Iohexol 350: 250 mL (87.5 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aortography and selective visceral arteriography: Iohexol 300 or 350 (may repeat up to a maximum total of 291 mL [iohexol 300] or 250 mL [iohexol 350]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aorta: 50 to 80 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Major branches, including celiac and mesenteric arteries: 30 to 60 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal arteries: 5 to 15 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cerebral arteriography: Iohexol 300:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Common carotid artery: 6 to 12 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Internal carotid artery: 8 to 10 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">External carotid artery: 6 to 9 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vertebral artery: 6 to 10 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Contrast enhanced CT:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Head imaging by injection:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 300: 70 to 150 mL (21 to 45 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 350: 80 mL (28 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Head imaging by infusion: Iohexol 240: 120 to 250 mL (29 to 60 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body imaging by injection:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 300: 50 to 200 mL (15 to 60 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 350: 60 to 100 mL (21 to 35 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digital subtraction angiography:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Iohexol 350: 30 to 50 mL (using a pressure injector; rate: 7.5 to 30 mL/second); 3 or more injections may be required; maximum total dose: 250 mL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intra-arterial: Iohexol 140:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Aorta: 20 to 45 mL (rate: 8 to 20 mL/second)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Carotid: 5 to 10 mL (rate: 3 to 6 mL/second)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Femoral: 9 to 20 mL (rate: 3 to 6 mL/second)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Vertebral: 4 to 10 mL (rate: 2 to 8 mL/second)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Renal: 6 to 12 mL (rate: 3 to 6 mL/second)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Other aorta branches (subclavian, axillary, innominate and iliac): 8 to 25 mL (rate: 3 to 10 mL/second)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peripheral angiography:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aortofemoral runoffs:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 300: 30 to 90 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 350: 20 to 70 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Selective arteriograms (femoral/iliac):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 300: 10 to 60 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 350: 10 to 30 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Venography (per leg):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 240: 20 to 150 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 300: 40 to 100 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretory urography: Iohexol 300 or 350: 200 to 350 mgI/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Oral/body cavity imaging: </b>\n      <b>Note:</b> gI = grams of iodine; mgI = mg of iodine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Contrast enhanced abdominal CT:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Iohexol diluted to 6 to 9 mgI/mL: 500 to 1,000 mL (use smaller volumes for higher concentrations)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV (in conjunction with dilute oral iohexol): Iohexol 300: 100 to 150 mL (administered ~20 to 40 minutes after oral diluted iohexol)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Contrast enhanced abdomen and pelvis CT: Oral (Oraltag): 500 mL to 1,000 mL administered 20 to 60 minutes before imaging; maximum total dose: 9 gI</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pass-through gastrointestinal examination: Oral: Iohexol 350 (undiluted): 50 to 100 mL (depending on patient size and the nature of the exam)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Arthrography: <b>Note:</b> Lower volumes recommended for double-contrast examinations; higher volumes recommended for single-contrast examinations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Knee joint:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 240 or 300: 5 to 15 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 350: 5 to 10 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Shoulder joint:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 240: 3 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 300: 10 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Temporomandibular joint: Iohexol 300: 0.5 to 1 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endoscopic retrograde pancreatography, cholangiopancreatography: Iohexol 240: 10 to 50 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hysterosalpingography: Iohexol 240 or 300: 15 to 20 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herniography: Iohexol 240: 50 mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983658\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=iohexol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Iohexol: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Concentration, volume, and rate may depend on the equipment, condition of injected vessel, size/condition of patient, and imaging technique used. Refer to prescribing information for detailed dosing and administration information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Intrathecal imaging: </b>\n      <b>Note:</b> gI = grams of iodine; mgI = mg of iodine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Myelography (lumbar, thoracic, cervical, and total columnar): Intrathecal: Iohexol 180 only:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0 to &lt;3 months: 2 to 4 mL (0.36 to 0.72 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">3 months to &lt;3 years: 4 to 8 mL (0.72 to 1.44 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">3 to &lt;7 years: 5 to 10 mL (0.9 to 1.8 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">7 to &lt;13 years: 5 to 12 mL (0.9 to 2.16 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">13 to 18 years: 6 to 15 mL (1.08 to 2.7 gI)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Single myelographic procedure: Do not exceed a concentration of 180 mgI/mL or total dose of iodine 2,700 mg. If a repeat procedure is required, wait at least 48 hours (5 to 7 days is preferred).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Intravascular imaging: Note:</b> gI = grams of iodine; mgI = mg of iodine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ventriculography:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Iohexol 300: 1.75 mL/kg (range: 1.5 to 2 mL/kg); if multiple injections are given, do not exceed 5 mL/kg or up to a total of 291 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Iohexol 350: 1.25 mL/kg (range: 1 to 1.5 mL/kg); if multiple injections are given, do not exceed 5 mL/kg or up to a total of 250 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pulmonary angiography: Iohexol 350: 1 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Combined angiocardiographic procedures: Maximum total dose for all procedures:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 300: 6 mL/kg or 291 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 350: 5 mL/kg or 250 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aortography and selective visceral arteriography: Iohexol 350: Usual single injection: 1 mL/kg; maximum total of 5 mL/kg or 250 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Contrast enhanced CT head imaging: Iohexol 240 or 300: 1 to 2 mL/kg; maximum dose: 28 gI (iohexol 240) or 35 gI (iohexol 300)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretory urography: Iohexol 300: Usual dose: 1 to 1.5 mL/kg (range: 0.5 to 3 mL/kg); maximum total dose: 3 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Oral/body cavity imaging: Note:</b> gI = grams of iodine; mgI = mg of iodine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pass-through gastrointestinal examination: Oral: Undiluted iohexol</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;3 months: Iohexol 180: 5 to 30 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">3 months to 3 years: Iohexol 180, 240, or 300: Up to 60 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">4-10 years: Iohexol 180, 240, or 300: Up to 80 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10 years: 180, 240, or 300: Up to 100 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Contrast enhanced abdomen and pelvis CT: Oral (Oraltag):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &lt;3 years: 120 mL to 300 mL (depending on size of patient) administered 20 to 60 minutes before imaging; maximum total dose: 4.5 gI</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents 3 to 18 years: 280 mL to 750 mL (depending on size of patient) administered 20 to 60 minutes before imaging; maximum total dose: 9 gI</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pass-through gastrointestinal examination: Rectal: Refer to Oral pass through gastrointestinal exam; however, larger volumes may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Contrast enhanced abdomen CT:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Iohexol diluted to 9 to 21 mgI/mL: 180 to 750 mL (use smaller volumes for higher concentrations); maximum: &lt;3 years: 5 gI; 3 to 18 years: 10 gI; may administer all at once or over 30 to 45 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV (in conjunction with dilute oral iohexol): Iohexol 240 or 300: 2 mL/kg (range: 1 to 2 mL/kg); maximum total IV dose: 3 mL/kg (administered ~30 to 60 minutes after oral diluted iohexol)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voiding cystourethrography: Iohexol diluted to 50 to 100 mgI/mL: Use a volume sufficient to fill the bladder (will depend on patient age and size; usual volume ranges from 50 to 300 mL at a concentration of 100 mgI/mL or 50 to 600 mL at a concentration of 50 mgI/mL.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15962260\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution in severe impairment and in the setting of combined renal and hepatic disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15962261\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution in the setting of combined hepatic and renal disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183882\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Omnipaque: 180 mg/mL (10 mL, 20 mL); 240 mg/mL (50 mL); 300 mg/mL (10 mL, 30 mL, 50 mL, 75 mL, 100 mL, 125 mL, 150 mL, 200 mL, 500 mL) [contains edetate calcium disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Omnipaque: 240 mg/mL (10 mL, 20 mL, 50 mL, 100 mL, 150 mL, 200 mL) [pyrogen free; contains edetate calcium disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Omnipaque: 140 mg/mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Omnipaque: 350 mg/mL (50 mL, 75 mL, 100 mL, 125 mL, 150 mL, 200 mL, 500 mL) [contains edetate calcium disodium]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183878\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983660\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydrate well prior to and following administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Intravascular:</b> Draw into syringe immediately prior to administration. Intravenous doses should be at body temperature prior to administration. In angiography, use meticulous intravascular administration technique to minimize thrombotic events including use of plastic syringes, frequent catheter flushing, and close attention to catheter and guide wire manipulation. When large individual volumes are administered (ie, for ventriculography or aortography), wait several minutes between each injection to allow possible hemodynamic disturbances to subside.</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; initiate hyaluronidase antidote; elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hyaluronidase:</i> Intradermal or SubQ: Inject a total of 1 mL (15 units/mL) as five separate 0.2 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (MacCara 1983; Zenk 1981) <b>or</b> injection of a total of 5 mL (150 units/mL) as five separate 1 mL injections around the extravasation site has been also used successfully (Rowlett 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Intrathecal:</b> Draw into syringe immediately prior to administration. Intrathecal doses should be administered slowly over 1 to 2 minutes (to avoid excessive mixing with CSF) through a lumbar or cervical needle under fluoroscopic control. <b>Note:</b> Use caution in product selection. For pediatric administration, use iohexol 180 only; for adults, use iohexol 180, 240, or 300 only. Iohexol 140 and 350 are <b>not</b> for intrathecal use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Discontinue neuroleptic medications (including phenothiazines) at least 48 hours prior to procedure. May maintain a normal diet up to 2 hours before the procedure. Ensure hydration fluids up to the procedure (hydrate well prior to and following administration). During the procedure, when positioning keep the patient&rsquo;s head elevated above the highest level of the spine; do not lower the head of the table more than 15&deg; in moving contrast medium cranially; consider a lateral position (administration and medium movement) in patients with lordosis; to maintain as a bolus, move medium very slowly to distal area; avoid intracranial entry of a bolus; avoid early and high cephalad medium dispersion; avoid abrupt or active patient movement. After the procedure, raise head of stretcher to at least 30&deg; prior to transferring patient on to it; move patient slowly, maintaining a head-up position; before moving patient to a bed, raise head to 30&deg; to 45&deg;; advise patient to remain still in bed, in a sitting or semi-sitting position, at least for the first few hours; observe closely for at least 12 hours; encourage oral fluids/diet as tolerated; if nausea and vomiting occur, do not use phenothiazines for management of nausea/vomiting; utilize prompt fluid replacement in the event of nausea/vomiting to prevent dehydration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Oral: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Omnipaque: Children: Large volumes of dilute oral solution may be administered all at once or over 30 to 45 minutes (if not tolerated all at once).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oraltag: If patient has difficulty consuming the required volume, a higher concentration of solution (up to 21 mgI/mL) can be prepared and a smaller volume administered. Administer 20 to 60 minutes before imaging.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183883\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;\">\n      <b>Imaging: </b>Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intrathecal: Iohexol 180, 240, and 300: Myelography (lumbar, thoracic, cervical, and total columnar), and contrast enhancement for CT (myelography, cisternography, ventriculography)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intravascular:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 140: Intra-arterial digital subtraction angiography of head, neck, abdominal, renal, and peripheral vessels</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 240: Contrast enhancement for CT head imaging and peripheral venography (phlebography)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 300: Aortography (including studies of aortic arch, abdominal aorta [and branches], contrast enhancement for CT head and body imaging, cerebral arteriography, peripheral venography (phlebography), and excretory urography</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 350: Angiocardiography (ventriculography, selective coronary arteriography), aortography (including studies of aortic root, aortic arch, ascending aorta, abdominal aorta [and branches]), contrast enhancement for CT head and body imaging, intravenous digital subtraction angiography of head, neck, abdominal renal and peripheral vessels, peripheral arteriography, and excretory urography</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral/body cavity:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol (diluted) and Iohexol 300: Contrast enhanced abdomen CT</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 240: Arthrography, endoscopic retrograde pancreatography and cholangiopancreatography, herniography, and hysterosalpingography</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 300: Arthrography, hysterosalpingography</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 350: Arthrography and oral pass-through gastrointestinal examination</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol (Oraltag): Contrast enhancement for CT abdomen and pelvis imaging</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Imaging:</b> Pediatrics:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intrathecal: Iohexol 180: Myelography (lumbar, thoracic, cervical, and total columnar), and contrast enhancement for CT (myelography, cisternography)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intravascular:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 240: Contrast enhancement for CT head imaging</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 300: Angiocardiography (ventriculography), contrast enhancement for CT head and body imaging, and excretory urography</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 350: Angiocardiography (ventriculography, pulmonary arteriography, and venography; studies of collateral arteries and aortography, including aortic root, aortic arch, ascending and descending aorta)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral/body cavity:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol (diluted): Voiding cystourethrography</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol 180, 240, and 300: Gastrointestinal tract examination</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol (diluted) and Iohexol 240 or 300: Contrast enhanced abdomen CT</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Iohexol (Oraltag): Contrast enhancement for CT abdomen and pelvis imaging</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174548\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983645\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Children generally have a lower frequency of reactions than adults.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac arrhythmia (digital arteriography: 7% to 16%; other intravascular uses: 2%; transient PVC and PACs most reported)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Pain (&le;49%, procedurally dependent), sensation of pressure (joint injection: 42%), headache (myelography: 9% to 18%; cerebral arteriography: 6%; all other uses: &le;3%), localized warm feeling (&le;13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (oral pass-thru: 36% to 42%; all other uses: &le;3%), nausea (&le;15%), vomiting (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Leg pain (phlebography: 21%; transient and mild)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Vision disturbance (cerebral arteriography: 15%, all other uses: &le;2%; photomas of &le;1 second), blurred vision (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Swelling (22%; mostly reported with arthrography and likely to be procedurally related)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Angina pectoris (angiocardiography: 8%; intravascular: &le;1%), hypotension (&le;3%), transient ischemic attacks (intravascular: &le;2%), abdominal distress (oral/body cavity: &le;1%), bradycardia (intravascular and angiocardiography: &le;1%), chest pain (intravascular: &le;1%), hypertension (&le;1%), syncope (&le;1%), tachycardia (intravascular and angiocardiography: &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Drowsiness (&le;3%), dizziness (&le;2%; usually transient), malaise (&le;1%), myasthenia (oral/body cavity; joint injection: &le;1%), vertigo (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Urticaria (intravascular; oral/body cavity: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Flatulence (herniography: 10%; oral/body cavity; oral pass-thru: &le;2%), abdominal pain (oral, adults: 7%; oral, children: 2%), dysgeusia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Hematoma at injection site (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (intrathecal, adults: &le;8%; intrathecal, children: 1%), neck pain (&le;8%), stiffness (&le;8%), tremor (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&le;5%; incidence higher in children receiving iohexol orally), sialadenitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Seizure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylactoid reaction, anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchospasm</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Sialadenitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abscess, anemia, anorexia, anxiety, apnea, asystole, cerebral infarction, cough, diaphoresis, difficulty in micturition, dyspepsia, dyspnea, feeling of heaviness, heart block, hemiparesis, hypertonia, hypoglycemia, laryngitis, motor dysfunction, muscle cramps, neuralgia, nystagmus, paresthesia, photophobia, pruritus, purpura, respiratory congestion, rhinitis, shivering, skin rash, speech disturbance, stomach pain, thrombophlebitis, tinnitus, vasodepressor syncope, ventricular tachycardia, visual hallucination, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183885\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to iohexol or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intrathecal:</b> Significant local or systemic infection where bacteremia is likely (myelography only); administration with intrathecal corticosteroids; for immediate repeat myelography. <b>Note:</b> Concentrations 140 and 350 are <b>not</b> for intrathecal use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Body cavity use: Hysterosalpingography:</b> Do not perform hysterosalpingography during menstrual period, when menstrual flow is imminent, or if infection is present in any portion of the genital tract, including the external genitalia; in pregnant women, if pregnancy is suspected, for 6 months after termination of pregnancy, or for 30 days after conization or curettage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Clinically significant impairment of both hepatic and renal function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983643\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contrast media reactions: Adverse reactions (including delayed reactions) to iodine-containing contrast media have occurred. Most cases are minor; however, serious and life-threatening reactions may occur without warning and often resemble allergic-type reactions. Patients with a history of bronchial asthma, allergy (including food allergy), family history of allergy, or prior allergy or hypersensitivity to contrast agents are at a higher risk for allergic reaction. Obtain allergy and hypersensitivity history prior to administration. Pretesting for allergic reaction may not reliably predict potential for reaction. Premedication with antihistamines and corticosteroids should be considered in patient at risk for allergic reaction (strong allergy history, prior contrast media reaction, or positive pretest) to reduce the incidence and severity of reactions. A higher incidence of adverse reactions was reported in patients also receiving general anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatological effects: Severe cutaneous adverse reactions (including Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN], acute generalized exanthematous pustulosis [AGEP], drug reaction with eosinophilia and systemic symptoms [DRESS]) have occurred 1 hour to several weeks after administration; reaction severity may increase and time to onset may decrease with repeat administration. Avoid use in patients with a history of a severe cutaneous adverse reaction to iohexol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant; ensure proper needle/catheter/line placement prior to and during administration. Avoid infiltration. Iohexol 240, 300, and 350 have osmolalities of 1.8 to 3 times that of plasma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal failure: Acute renal failure has been reported in diabetic patients with diabetic nephropathy and susceptible nondiabetic patients (eg, elderly patients with preexisting renal disease). Preparatory dehydration may contribute to acute renal failure in infants, young children and elderly patients, patients with preexisting renal impairment, multiple myeloma, advanced vascular disease, and diabetes; avoid fluid restriction and maintain normal hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients with history of epilepsy. Antiepileptic therapy should be maintained. Prophylactic anticonvulsant therapy should be considered in patients with a seizure history but not currently on antiseizure therapy, and in those with evidence of inadvertent intracranial entry of a concentrated or large bolus of contrast media. CNS-acting agents, primarily those which lower seizure threshold (eg, phenothiazines, MAO inhibitors, tricyclic antidepressants, SSRIs), should be discontinued 24 to 72 hours prior to intrathecal use and not resumed for 24 hours post procedure (ACR 2008). Major motor seizures with nonionic myelographic media are generally associated with one or more of the following situations (avoid situation): Deviations from recommended procedures or in myelographic management; use in patients with history of epilepsy; overdosage; intracranial entry of bolus or premature diffusion of a high medium concentration; medication with neuroleptic drugs or phenothiazine agents for antinausea; failure to maintain head elevation during and following the procedure; and excessive and active patient movement/straining.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: Serious, rarely fatal, thromboembolic events causing MI and stroke have been reported with both ionic and nonionic contrast media. Ionic iodinated contrast media may inhibit blood coagulation (more than nonionic contrast media). Use meticulous intravascular administration techniques during angiographic procedures. Clotting has been reported when in vitro blood remains in contact with syringes containing nonionic contrast media; use of plastic syringes in place of glass syringes has been reported to decrease, but not eliminate, the likelihood of in vitro clotting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with severe cardiovascular disease. Observe patients with heart failure for several hours after procedure for development of delayed hemodynamic changes. Perform selective coronary angiography only if the anticipated benefit outweighs potential risks. Preparatory dehydration may contribute to acute renal failure in patients with advanced vascular disease; avoid fluid restriction and maintain normal hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic alcoholism: Use caution in patients with alcoholism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatorenal insufficiency: Do not use in patients with hepatorenal insufficiency unless the benefits clearly outweigh risks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Preparatory dehydration may contribute to acute renal failure in patients with diabetes; avoid fluid restriction and maintain normal hydration in these patients. Diabetics with a serum creatinine level &gt;3 mg/dL should not be examined unless the benefits clearly outweigh the risks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with combined renal and hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Homocystinuria: Avoid angiography in patients with homocystinuria; may be at risk for thrombosis and embolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Thyroid storm following intravascular administration of iodinated contrast media have occurred in patients with hyperthyroidism or with an autonomously functioning thyroid nodule.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypothyroidism: Thyroid function tests indicative of hypothyroidism or transient thyroid suppression have been reported (uncommon) in adult and pediatric patients (including infants). Some patients were treated for hypothyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple myeloma: Use with caution in patients with multiple myeloma or other paraproteinemia, particularly in those with resistant anuria; use of intravascular contrast agents may lead to renal impairment, especially with concurrent dehydration. Partial dehydration in preparation for the procedure is not recommended in these patients because it may contribute to precipitation of the myeloma protein in the renal tubules.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple sclerosis: Use with caution in patients with multiple sclerosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pheochromocytoma: Use with extreme caution in patients with pheochromocytoma (known or suspected). Minimize the amount of contrast agent used (for intravascular administration) and monitor blood pressure closely throughout procedure. Therapy to manage hypertensive crisis should be readily available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary disease: The risks of angiocardiography in patients with chronic pulmonary emphysema should be weighed against the necessity for the procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment and/or combined renal and hepatic impairment. Not recommended in patients with anuria. Preparatory dehydration may contribute to acute renal failure in patients with preexisting renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sickle cell disease: Use with caution in sickle cell disease; may promote sickling in patients homozygous for sickle cell disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly. Elderly patients may present a greater risk following intrathecal administration for myelography. Carefully evaluate the need for myelography in elderly patients. Special attention must be paid to dose and concentration of the medium, hydration, and technique used. Preparatory dehydration may contribute to acute renal failure in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Pediatric patients at higher risk of experiencing adverse events during contrast medium administration may include those having asthma, sensitivity to medication or allergens, heart failure, serum creatinine &gt;1.5 mg/dL, or those &lt;12 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <i>Intrathecal administration:</i> Only iohexol 180, 240, and 300 are indicated for intrathecal administration. <b>[US Boxed Warning]: Iohexol 140, 300 (imaging bulk), and 350 are NOT for intrathecal use;</b> precautions should be taken to ensure that iohexol 140 or 350 is not administered intrathecally. Serious adverse reactions (eg, cerebral hemorrhage, seizures, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, brain edema, death) have been reported due to inadvertent intrathecal administration of iodinated contrast agents not indicated for intrathecal use. If CSF is grossly bloody, evaluate the possible benefits of myelographic procedure versus potential risks to the patient. Avoid inadvertent intracranial administration of large dose or concentrated bolus of contrast medium; avoid rapid dispersion of medium, which could lead to inadvertent rise in intracranial levels (as may occur with active patient movement). Direct intracisternal or ventricular administration for standard radiograph (not CT) is not recommended. If repeat procedure is required, a sufficient time in between should be used to allow for clearance (&ge;48 hours; 5 to 7 days is recommended).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <i>Intravascular administration:</i> In angiographic procedures, during catheter manipulations and contrast medium injection, a possibility of dislodging plaques or damaging (or perforating) vessel walls exists. Ensure proper catheter placement with test injections. In situations of slow aortic circulations, there is an increased incidence of muscle spasm. Serious neurologic complications (including paraplegia) have been reported in patients with aortoiliac obstruction, femoral artery obstruction, abdominal compression, hypotension, hypertension, spinal anesthesia, and injection of vasopressors to increase contrast; maintain minimum contrast concentration, volume, and the number of repeat injections and allow appropriate intervals between injections; monitor patient position and catheter tip. Administration of a large aortic dose into the renal artery may cause (reversible) albuminuria, hematuria, and elevated BUN and serum creatinine. Cerebral arteriography should be done with extreme care/caution in elderly patients, patients in poor clinical condition, with advanced arteriosclerosis, severe arterial hypertension, recent cerebral embolism or thrombosis, cardiac decompensation; monitor closely for central nervous system reactions. High-pressure administration may cause rupture of smaller peripheral arteries or veins. In excretory urography, due to a risk of temporary suppression of urine formation, allow an appropriate interval to elapse before repeat excretory urography. Patients with diabetes with a serum creatinine &gt;3 mg/dL should not be examined unless the benefits outweigh the additional risk. Not recommended for use in patients with anuria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <i>Oral/body cavity administration:</i> Hypertonic contrast media can draw fluid into the intestinal lumen causing plasma fluid loss and diarrhea; with severe loss hypovolemia results and in some cases a shock-like state. Elderly, cachectic patients, children, and infants are especially susceptible. For arthrography, fluoroscopic control should be used to ensure proper needle placement, prevent extracapsular injection, and prevent dilution of contrast medium; undue pressure should not be used during injection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Oral administration (Oraltag): Do not administer parenterally; serious adverse reactions such as sepsis may occur. Not indicated for diagnostic examination of the GI tract.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Trained personnel: Clinicians using radiopaque contrast agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use during and for 30 to 60 minutes after administration (delayed reactions have occurred).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299530\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6221091\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8927&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents With Seizure Threshold Lowering Potential: May enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Iodinated Contrast Agents may enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis.  Management: Management advice varies. Refer to the full drug interaction monograph content for details.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183880\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183887\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Use for hysterosalpingography is contraindicated during pregnancy. In general, iodinated contrast media agents may cross the placenta; use should be avoided unless absolutely required to obtain diagnostic information that will influence the care of the mother or fetus during pregnancy (ACOG 2016; ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183888\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Because of the low expected excretion of iodinated contrast agents into breast milk and the low absorption from an infant&rsquo;s GI tract, breast-feeding may be continued without interruption after use (ACOG 2016; ACR 2015). Theoretically, the taste of milk could be altered if it contains contrast media. Women who prefer to temporarily withhold breast-feeding can pump and store milk prior to the procedure and abstain from nursing for 12 to 24 hours (ACR 2015). The manufacturer recommends that caution be exercised; however, bottle feedings may be substituted for breast-feeding for 24 hours after contrast administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23897845\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for extravasation during IV administration; monitor for hypersensitivity reactions for &ge;30 to 60 minutes. Continuously monitor vital signs when administering large doses of iohexol 350.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983651\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Opacification of vessels and anatomical structures in the path of flow of the contrast media which allows for radiographic visualization</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983653\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CNS: ~30 minutes following intrathecal administration, 60 minutes following intravenous administration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum: 15 to 120 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Poorly absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Not significantly metabolized</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Minimal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (Intrathecal, Intravascular: ~88% to 90%, as unchanged drug; Oral: &lt;1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323204\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Omnipaque Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg/mL (10 mL): $56.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 mg/mL (50 mL): $46.89</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/mL (50 mL): $55.47</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Omnipaque Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">140 mg/mL (50 mL): $40.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">350 mg/mL (50 mL): $58.66</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183889\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Diapac 350 (BD);</li>\n      <li>Hexosure (KR);</li>\n      <li>Imiro 350 (BD);</li>\n      <li>Iobrix (KR, TH);</li>\n      <li>Medixol 350 (PE);</li>\n      <li>Omnipak (UA);</li>\n      <li>Omnipaque (AE, AT, AU, BE, BG, CH, CL, CO, CY, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GB, GR, HN, HR, IE, IL, IS, IT, JO, KW, LK, LT, LU, LV, MT, NL, NO, NZ, PH, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, TR, UY, VE, VN);</li>\n      <li>Radiopaque (IN);</li>\n      <li>Yoheksol (UA);</li>\n      <li>Yunipak (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee Opinion No. 656: guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2016;127(2):e75-e80. doi:10.1097/AOG.0000000000001316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iohexol-drug-information/abstract-text/26942391/pubmed\" target=\"_blank\" id=\"26942391\">26942391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 10.1. http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2015_Contrast_Media.pdf. Published 2015. Accessed April 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology, &ldquo;Manual on Contrast Media, Version 7.0&rdquo;, 2010. Available at http://gm.acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual.aspx</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology, &ldquo;Practice Guideline for the Performance of Myelography and Cisternography,&rdquo;2008. Available at http://gm.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/dx/head-neck/myelography.aspx</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FDA Safety Alert. MedWatch. Iodine-containing contrast agents for medical imaging. Food and Drug Administration website. <a href=\"http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm472995.htm\" target=\"_blank\">http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm472995.htm</a>. Updated November 17, 2015. Accessed November 18, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2012, 126(7):875-910.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iohexol-drug-information/abstract-text/22800849/pubmed\" target=\"_blank\" id=\"22800849\">22800849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klein LW, Sheldon MW, Brinker J, et al, &ldquo;The Use of Radiographic Contrast Media During PCI: A Focused Review: A Position Statement of the Society of Cardiovascular Angiography and Interventions,&rdquo; <i>Catheter Cardiovasc Interv</i>, 2009, 74(4):728-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iohexol-drug-information/abstract-text/19830793/pubmed\" target=\"_blank\" id=\"19830793\">19830793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Laskey WK, Jenkins C, Selzer F, et al, &ldquo;Volume-to-Creatinine Clearance Ratio: A Pharmacokinetically Based Risk Factor for Prediction of Early Creatinine Increase After Percutaneous Coronary Intervention,&rdquo; <i>J Am Coll Cardiol</i>, 2007, 50(7):584-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iohexol-drug-information/abstract-text/17692741/pubmed\" target=\"_blank\" id=\"17692741\">17692741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iohexol-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iohexol-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Omnipaque (iohexol) injection 140, 180, 240, 300, and 350 [prescribing information]. Marlborough, MA: GE Healthcare Inc; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Omnipaque Pharmacy Bulk (iohexol) injection 300 and 350 [prescribing information]. Marlborough, MA: GE Healthcare Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Omnipaque (iohexol) [product monograph]. Mississauga, Ontario, Canada; GE Healthcare Canada Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oraltag (iohexol) [prescribing information]. New Paltz, NY: Ultra Seal Corporation; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oraltag (iohexol) [prescribing information]. New Paltz, NY: Ultra Seal Corporation; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowlett J. Extravasation of contrast media managed with recombinant human hyaluronidase. <i>Am J Emerg Med</i>. 2012;30(9):2102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iohexol-drug-information/abstract-text/22633726/pubmed\" target=\"_blank\" id=\"22633726\">22633726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8927 Version 116.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F26524993\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F183891\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9617644\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F183894\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F7983659\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F7983658\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15962260\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15962261\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F183882\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F183878\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F7983660\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F183883\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5174548\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F7983645\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F183885\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F7983643\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299530\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6221091\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F183880\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F183887\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F183888\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F23897845\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F7983651\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F7983653\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323204\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F183889\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8927|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=iohexol-patient-drug-information\" class=\"drug drug_patient\">Iohexol: Patient drug information</a></li><li><a href=\"topic.htm?path=iohexol-pediatric-drug-information\" class=\"drug drug_pediatric\">Iohexol: Pediatric drug information</a></li></ul></div></div>","javascript":null}